期刊文献+

特发性膜性肾病血清抗磷脂酶A 2受体抗体与免疫治疗关系的研究 预览

Relationship between serum anti-phospholipase A2 receptor antibodies and immunotherapy of the patients with idiopathic membranous nephropathy
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:观察特发性膜性肾病(idiopathic membranous nephropathy,IMN)血清抗磷脂酶A2受体(phospholipase A2 receptor,PLA2R)抗体表达情况,探讨血清抗PLA2R抗体和免疫治疗疗效的关系。方法:选取经肾活检确诊为IMN的患者60例,用间接免疫荧光法检测血清抗PLA2R抗体,免疫组织化学染色后观察肾组织PLA2R的表达。根据血清抗PLA2R抗体检测结果,将患者分为血清抗PLA2R抗体阳性组44例,血清抗PLA2R抗体阴性组16例,均给予激素联合环磷酰胺方案治疗,疗程12个月。观察治疗前后24h尿蛋白、血清白蛋白、血肌酐、估计肾小球滤过率(glomerular filtration rate,eGFR)变化以及血清抗PLA2R抗体转阴情况。结果:(1)60例IMN患者在基线时检测血清抗PLA2R抗体阳性为44例,阳性率73.3%。基线时血清抗PLA2R抗体阳性患者肾组织PLA2R表达也呈阳性。(2)抗PLA2R抗体阴性组患者24h尿蛋白、血白蛋白恢复情况优于抗PLA2R抗体阳性组(P<0.05)。(3)治疗6个月后抗PLA2R抗体阳性和阴性组总缓解率分别为47.7%和93.9%,治疗12个月总缓解率分别为56.8%和100%。结论:血清抗PLA2R抗体是IMN的特异性生物标志物。血清抗PLA2R抗体阳性的患者免疫治疗效果差。IMN患者检测血清抗PLA2R抗体有助于判断病情,对于治疗策略的选择和病情的监测具有重要意义。 Objective :To observe the expression of serum anti-phospholipase A 2 receptor (PLA 2R) antibodies in idiopathic membranous nephropathy (IMN),and also to explore the relationship between serum anti-PLA 2R antibodies and immunotherapy.Methods :Serum anti-PLA 2R antibodies and immunohistochemical staining were used to detect the expression levels of anti-PLA 2R antibodies in the renal tissue of 60 IMN patients.According to the detection results of serum anti-PLA 2R antibodies,they were divided into the positive group (44 cases) and the negative group (16 cases).The two groups were all treated with hormone combined with cyclophosphamide for a treatment course of 12 months.The changes in 24-h urinary protein,serum albumin, serum creatinine and glomerular filtration rate (eGFR) were observed before and after the treatment.And negative turning of serum anti-PLA 2R antibodies before and after the treatment was also observed.Results :(1) Of the 60 patients with IMN,there were 44 patients with positive serum anti-PLA 2R antibodies at baseline,with a positive rate of 73.3%.The expression of anti-PLA 2R antibodies in the renal tissue of the patients with positive serum anti-PLA 2R antibodies was also positive at baseline.(2) 24-h urinary protein and serum albumin recovery of the patients in the negative group were better than those in the positive group ( P <0.05).(3)The total remission rates of the anti-PLA 2R antibodies in the positive group and the negative group were 47.7% and 93.9% respectively after 6 months of the treatment,and total remission rates of the 2 groups were 56.8% and 100% respectively after 12 months of the treatment.Conclusion :Serum anti-PLA 2R antibodies is a specific biomarker of IMN.Patients with positive serum anti-PLA 2R antibodies show poor immunotherapy effect.Detection of serum anti-PLA 2R antibodies in the IMN patients is helpful to judge the illness condition of the patient,and is of great importance for the choice of treatment strategy and monitoring of the disease.
作者 唐琦 邬碧波 李林 郝晓萍 胡小华 张黎明 TANG Qi;WU Bibo;LI Lin;HAO Xiaoping;HU Xiaohua;ZHANG Liming(Department of Nephrology,Zhabei Central Hospital of Jing'an District,Shanghai 200070,China;Department of Nephrology,Changzheng Hospital,Navy Military Medical University and Kidney Disease Institute of PLA,Shanghai 200003,China)
出处 《药学服务与研究》 CAS 2019年第3期180-184,共5页 Pharmaceutical Care and Research
基金 上海市科学技术委员会科研计划项目(124119b1000) 上海市闸北区卫生科研课题(2012ZD03)。
关键词 特发性膜性肾病 血清抗磷脂酶A2受体抗体 免疫治疗 idiopathic membranous nephropathy serum anti-phospholipase A 2 receptor antibody immunotherapy
  • 相关文献

参考文献5

二级参考文献68

  • 1Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges [J]. Nat Rev Nephrol, 2012, 8(4): 203- 213. 被引量:1
  • 2Glassock RJ. The pathogenesis of membranous nephropathy: evolution and revolution [J]. Curr Opin Nephrol Hypertens, 2012, 21(3): 235- 242. 被引量:1
  • 3Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy [J].J Am Soc Nephrol, 2014, 25(6): 1357- 1366. 被引量:1
  • 4Kanigicherla Dj Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy [J]. Kidney Int, 2013, 83(5): 940-948. 被引量:1
  • 5Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2014, 9(8): 1386-1392. 被引量:1
  • 6Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cceres C, et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus [J]. Nefrologia, 2014j 34(4): 491-497. 被引量:1
  • 7Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Int Supplp 2012, 2: 186-197. 被引量:1
  • 8Ojn W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy [J]. J Am Soc Nephrol, 2011, 22(6): 1137-1143. 被引量:1
  • 9Hofstra JM, Debiec H, Short CDj et al. Antiphosphohpase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy [J]. J Am Soc Nephral, 2012, 23(10): 1735-1743. 被引量:1
  • 10Hoxha E, Kneiler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy [J]. Kidney Int, 2012, 82(7): 797-804. 被引量:1

共引文献39

投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈